British Supreme Court rules in Eli Lilly’s favor in drug dispute
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
A small, little-known company purchased at auction the company’s intellectual property rights, besting a bid by a large retailer with a household name.
The justices ruled unanimously Monday that patent infringement lawsuits can be filed only in states where defendants are incorporated. The case was sparked by an appeal from Carmel-based TC Heartland LLC.
The U.S. Supreme Court agreed to consider putting sharp new limits on where patent-infringement lawsuits can be filed, accepting a case that may undercut patent owners’ ability to channel cases to favorable courts.
Carmel-based Heartland Consumer Products LLC, which owns the rights to the Splenda brand, says Dunkin’ Donuts uses a knockoff sweetener but leads customers to believe it uses Splenda.
The Senate easily passed a bill Monday allowing corporations to make a federal case of the theft of trade secrets, but a broader patent-law overhaul backed by businesses including Eli Lilly and Co. faces a rougher road.
Texas A&M University says it has reached a settlement agreement with the Indianapolis Colts in the school's federal lawsuit it says was meant to protect its "12th Man" trademark from infringement.
In one fell swoop, the law firm more than doubled the size of its intellectual property team with the additions it scored from Krieg DeVault. The move could bring as much as $10 million in annual revenue to Taft.
The optimism bias creates a common expectation and perception of innovation value versus real value.
Purdue University officials are asking their legal counsel to look into a new movie that makes frequent references to the school despite its refusal to grant permission to use official trademarks and logos.
As Aereo Inc.’s streaming-TV service was dealt a potentially fatal blow Wednesday, the cloud-computing industry was more concerned about what the U.S. Supreme Court didn’t say.
The U.S. Patent Office ruled Wednesday that the Washington Redskins nickname is "disparaging of Native Americans" and that the team's federal trademarks for the name must be canceled.
The agreement was announced hours before the NCAA went to federal court in California to defend itself against a class-action lawsuit from former players over use of their images in broadcasts and video games.
The U.S. Supreme Court ruled against patent holders in two cases Monday, rejecting a legal theory used to sue technology companies and requiring patents to be written with more specific language.
The settlement is with Electronic Arts and Collegiate Licensing Co., which licenses and markets college sports, and does not include the NCAA. A separate case against the Indianapolis-based NCAA is scheduled for trial early next year.
The court noted that after the government filed a second indictment March 12, the trade-secret theft claims against Guoqing Cao and Shuyu Li were changed to wire fraud, and aiding and abetting and conspiracy to commit wire fraud.
Attorney Richard Bell says he has found about 300 people using a photo on their websites that he took back in 2000. His aggressive litigation against them raises vital questions about fair use and theft in the Internet age.
“Troll” is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
The Indianapolis-based fundraising-software developer claims it is the victim of cybersquatting, according to a federal lawsuit it filed against InterMediaOne and InterMediaOne-AGM.
Paris-based Sanofi sued Eli Lilly and Co. on Thursday for patent infringement. That suit triggers an automatic 30-month delay on Lilly’s plans to launch a similar version of Sanofi’s once-a-day insulin Lantus.